Novavax Q1 revenue exceeds expectations, continues to advance cost reduction and efficiency improvement

Glonghui, May 6 — Vaccine manufacturer Novavax announced that, thanks to the strong performance of its vaccine business, first quarter revenue reached $140 million, surpassing analysts’ average expectation of $78.3 million. The company is continuing to promote cost reduction and efficiency measures, aiming to keep combined R&D and administrative expenses at approximately $325 million in 2026, and to reduce this to $225 million in 2027.